Consero 2015 IP Forum for Pharmaceuticals and Biotechnology


Fish is proud to sponsor the 2015 IP Forum for Pharmaceuticals and Biotechnology in Coral Gables, Florida, December 6-8, 2015. Gwilym Attwell is Chair of the Forum. Consero's 2015 IP Forum for Pharmaceuticals & Biotechnology will address current legal and business challenges faced by today's Chief IP and Chief Patent Counsel, providing a unique opportunity to share best practices and strategies that will help lead their departments and companies in the right direction.

In addition to acting as Chair of the Forum, Gwilym Attwell is moderating the panel, “Three Years After The AIA: What Have We Learned?” on December 7. Todd Garcia (Boston) is moderator of the panel “Navigating A Shifting Biopharmaceutical Paradigm” on December 7. Dorothy Whelan (Minneapolis) is moderator of the panel “A View From The Trenches Of The Most-Active Forum For Patent Validity Challenges -The PTAB” on December 7.

Monday, December 7

8:00 AM – 9:00 AM: Navigating A Shifting Biopharmaceutical Paradigm

  • What is the current global landscape for biopharmaceuticals? What new trends have influenced your strategy for 2015 and 2016?
  • What role do trade secrets play in biopharmaceuticals, and how will they affect FDA regulation? What does this mean for your company's pipeline?
  • How have you formulated your departmental strategy regarding biosimilars and follow-on biologics despite the uncertainty of how they will be implemented by the FDA?


Robert Barker, Chief IP Counsel, Biologics

Medtronic Sofamor Danek, USA, Inc.

Chuck Sholtz, Vice President, Intellectual Property

Coherus Biosciences


Todd Garcia, Principal

Fish & Richardson P.C.

9:00 AM – 10:00 AM: A View From The Trenches Of The Most-Active Forum For Patent Validity Challenges -The PTAB

In 2014, the PTAB overtook the Eastern District of Texas to become the most-active forum for patent validity challenges. With an increasing number of life sciences patents and at the PTAB, what lessons can we learn and apply from the last three years of post-grant practice? In this interactive session, we will address recent developments that impact frequency of institution, the extensiveness of discovery, and the reach of estoppel. We’ll also discuss what is likely to come in the future.


Dorothy Whelan, Principal

Fish & Richardson P.C.

1:00 PM – 2:00 PM: Three Years After The AIA: What Have We Learned

  • In what ways have you retooled your global IP strategy to include the most recent provisions in the AIA?
  • Has the AIA tangibly changed your approach to the in-house patent process?
  • How has the AIA changed the way you educate business leaders and in-house inventors about the value of IP?


James Kellerman, Vice President, Intellectual Property

Astellas US

Marlan Walker, Chief Legal Officer, Intellectual Property


Zoran Zdraveski, Chief Intellectual Property Counsel

Epizyme, Inc.


Gwilym Attwell, Principal

Fish & Richardson P.C.